Your browser doesn't support javascript.
loading
Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?
Koufakis, Theocharis; Mustafa, Omar G; Tsimihodimos, Vasilios; Ajjan, Ramzi A; Kotsa, Kalliopi.
Affiliation
  • Koufakis T; Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, 1 St. Kiriakidi Street, 54636, Thessaloniki, Greece.
  • Mustafa OG; Department of Diabetes, King's College Hospital, London, UK.
  • Tsimihodimos V; Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece.
  • Ajjan RA; Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
  • Kotsa K; Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, 1 St. Kiriakidi Street, 54636, Thessaloniki, Greece. kalmanthou@yahoo.gr.
Drugs ; 81(12): 1365-1371, 2021 Aug.
Article in En | MEDLINE | ID: mdl-34232488
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Sodium-Glucose Transporter 2 Inhibitors Type of study: Clinical_trials Limits: Humans Language: En Journal: Drugs Year: 2021 Document type: Article Affiliation country: Greece Country of publication: New Zealand
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Sodium-Glucose Transporter 2 Inhibitors Type of study: Clinical_trials Limits: Humans Language: En Journal: Drugs Year: 2021 Document type: Article Affiliation country: Greece Country of publication: New Zealand